TrialJournal of hematology & oncology2026

Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.

Sankalp Arora et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.